Approval · Notice of Compliance 9170 · 2007
RASILEZ: Notice of Compliance 9170
Issued November 14, 2007
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 9170
- Date
- November 14, 2007
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Renin inhibitor
Products in this notice
Medicinal ingredients
- ALISKIREN FUMARATE 150 MG per TAB
- ALISKIREN FUMARATE 300 MG per TAB